Zontivity
(Vorapaxar)ApprovedSmall molecule
Akero TherapeuticsZontivity is one of 96 small molecule programs targeting Myocardial Infarction. It is currently in Approved.
2
Indications
11
Total Trials
0
Active Trials
95
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
111 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Onglyza
AstraZenecaApproved
Precose
BayerApproved
Diabeta
PfizerApproved
Viagra
VViatris Specialty LLC
Approved
Protonix
WWyeth-Lederle Vaccines
Approved
Tricor
JJagotec
Approved
Inpefa
LLexicon Pharmaceuticals
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Zontivity
Akero TherapeuticsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Coronary Syndrome2 trials
Atherosclerosis2 trials
Myocardial Infarction1 trial
4 more indications
Coagulation1 trial
Cerebral Infarction1 trial
Diabetes Mellitus1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
May 8, 2014
ZONTIVITY
NDA NDA204886
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vorapaxar. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[5]
Patent Cliff
Dec 23, 2027
Earliest patent expiration — generic entry possible after this date
Patent #Expires
7304078Dec 23, 2027